dolutegravir OAD

Phase 3

GSK plc (GSK)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Infection, Human Immunodeficiency Virus

View Full Landscape

Drug Information

Target Indication

Infection, Human Immunodeficiency Virus

Clinical Trial

NCT01449929

Last updated: 10/25/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA1/16/2014

Tivicay

Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg. Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children of at least 4 weeks of age or older and weighing at least 3 kg.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

GSK

GSK plc

Pharmaceutical Preparations•Europe•NYSE

Related Pipeline

Combined Hepatitis A and B vaccinePhase 3

Hepatitis B

GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)Phase 3

Infections, Meningococcal